- Home
- ATRO vs MYGN Comparison
ATRO vs MYGN Comparison
Compare ATRO & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRO
- MYGN
- Stock Information
- Founded
- ATRO 1968
- MYGN 1991
- Country
- ATRO United States
- MYGN United States
- Employees
- ATRO N/A
- MYGN N/A
- Industry
- ATRO Military/Government/Technical
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- ATRO Industrials
- MYGN Health Care
- Exchange
- ATRO Nasdaq
- MYGN Nasdaq
- Market Cap
- ATRO 844.1M
- MYGN 744.7M
- IPO Year
- ATRO N/A
- MYGN 1995
- Fundamental
- Price
- ATRO $34.44
- MYGN $4.51
- Analyst Decision
- ATRO Strong Buy
- MYGN Hold
- Analyst Count
- ATRO 1
- MYGN 15
- Target Price
- ATRO $49.00
- MYGN $15.14
- AVG Volume (30 Days)
- ATRO 710.6K
- MYGN 1.3M
- Earning Date
- ATRO 07-31-2025
- MYGN 08-05-2025
- Dividend Yield
- ATRO N/A
- MYGN N/A
- EPS Growth
- ATRO N/A
- MYGN N/A
- EPS
- ATRO N/A
- MYGN N/A
- Revenue
- ATRO $816,288,000.00
- MYGN $831,300,000.00
- Revenue This Year
- ATRO $8.33
- MYGN N/A
- Revenue Next Year
- ATRO $5.89
- MYGN $6.68
- P/E Ratio
- ATRO N/A
- MYGN N/A
- Revenue Growth
- ATRO 13.73
- MYGN 7.38
- 52 Week Low
- ATRO $14.13
- MYGN $3.81
- 52 Week High
- ATRO $37.32
- MYGN $29.30
- Technical
- Relative Strength Index (RSI)
- ATRO 61.79
- MYGN 40.01
- Support Level
- ATRO $34.22
- MYGN $4.97
- Resistance Level
- ATRO $37.32
- MYGN $5.37
- Average True Range (ATR)
- ATRO 1.48
- MYGN 0.28
- MACD
- ATRO 0.14
- MYGN -0.07
- Stochastic Oscillator
- ATRO 75.17
- MYGN 2.34
About ATRO Astronics Corporation
Astronics Corp supplies products to the aerospace, defense, and electronics industries. The company has two reportable segments namely Aerospace and Test Systems. The aerospace segment serves three primary markets: military, commercial transport, and General Aviation. The Test Systems segment serves the aerospace, defense, and semiconductor markets. The company generates a majority of its revenue from the Aerospace segment. Geographically, it generates a majority of its revenue from the United States.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.